Isomorphic Labs Raises $2.1 Billion in Series B Funding to Expand AI Drug Discovery Platform
Top Picks
Stay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
Isomorphic Labs, a London-based company developing AI-powered drug design technology, has raised $2.1 billion in Series B funding.
The round was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The company said it will use the funding to advance its AI drug design engine, expand therapeutic research programs toward clinical trials, and grow teams across AI, engineering, and clinical research functions.
Isomorphic Labs Focuses on AI-Based Drug Discovery
Founded by Demis Hassabis, Isomorphic Labs develops AI systems designed to support drug discovery and development.
The company’s platform, known as IsoDDE, uses foundational AI models to predict and generate potential drug molecules across multiple therapeutic areas. According to Isomorphic Labs, the system builds on research advancements beyond the AlphaFold protein structure prediction technology.
Max Jaderberg currently serves as president of the company.
Funding to Support Clinical Development
Isomorphic Labs said the new capital will help move more therapeutic programs toward clinical trial stages. In addition, the company plans to expand its global workforce as it scales research and operational capabilities.
The company aims to apply AI models to better understand biological systems and accelerate parts of the drug discovery process that traditionally require extensive laboratory research and development timelines.
Strategic Partnerships With Pharmaceutical Companies
The company has already established research partnerships with several major pharmaceutical firms, including Novartis, Eli Lilly and Company, and Johnson & Johnson.
According to Isomorphic Labs, these collaborations are intended to validate and expand its AI-first approach to drug discovery across multiple disease areas.
The broader pharmaceutical sector has seen growing interest in AI-driven drug development as companies look to improve research efficiency and shorten development timelines.
